NASDAQ:GEMP Gemphire Therapeutics (GEMP) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free GEMP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.08▼$3.3050-Day Range$0.30▼$6.3852-Week Range$0.24▼$1.49Volume23,389 shsAverage Volume127,174 shsMarket Capitalization$46.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Gemphire Therapeutics alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Gemphire Therapeutics Stock (NASDAQ:GEMP)Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. GEMP Stock News HeadlinesMay 11, 2023 | marketwatch.comHypertriglyceridemia Treatment Market Detect New Industry Opportumities 2023-2030April 28, 2023 | marketwatch.comNonalcoholic Steatohepatitis (NASH) Market 2023: Share and Growth Opportunities Forecast till 2030April 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 12, 2023 | marketwatch.com2023-2031 Non-Alcoholic Steatohepatitis Market: Latest UpdatesApril 12, 2023 | marketwatch.com2023-2031 Non-Alcoholic Steatohepatitis Market: Latest UpdatesMarch 29, 2023 | marketwatch.comNonalcoholic Steatohepatitis (NASH) Market Growth and Industry Insights till 2027March 26, 2023 | marketwatch.comGlobal Hypercholesterolemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By VMReportsMarch 24, 2023 | marketwatch.com2023 Hypertriglyceridemia Treatment Market Size, Growth | Global Industry Trends [2029]April 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 2, 2023 | marketwatch.comHypertriglyceridemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029March 1, 2023 | marketwatch.comHypertriglyceridemia Treatment Market 2023 Growth, Trends With the Rise in ICT Industry 2029February 17, 2023 | marketwatch.comLatest Hypertriglyceridemia Treatment Market Research Report (2023-2028)-Key Takeaways from Top CompaniesFebruary 15, 2023 | marketwatch.comWorldwide Nonalcoholic Steatohepatitis (NASH) Market 2023 with Growth Analysis by Size and Share to 2027 | 99 PagesJanuary 24, 2023 | finance.yahoo.comBiVictriX Therapeutics makes 'fundamental step forward'April 6, 2022 | marketwatch.comHypertriglyceridemia Treatment Market Size 2022 Analysis Growth Report by Trends, Applications, Types, Competitive Strategies and Forecast to 2029March 31, 2022 | marketwatch.comGlobal Hypercholesterolemia Treatment Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028October 13, 2021 | markets.businessinsider.comNeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without ModificationSee More Headlines Receive GEMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2019Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GEMP CUSIPN/A CIK1638287 Webwww.gemphire.com Phone734-245-1700FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-419.70% Return on Assets-173.05% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book6.24Miscellaneous Outstanding Shares14,872,000Free FloatN/AMarket Cap$50.12 million OptionableNot Optionable Beta2.82 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Charles L. Bisgaier (Age 65)Co-Founder, Chairman & Chief Scientific Officer Dr. Steven R. Gullans (Age 66)CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer Mr. Seth Reno (Age 52)Chief Commercial Officer Mr. Jeffrey S. Mathiesen C.P.A. (Age 58)CPA, Consultant Ms. Amy Zaremba RabournDirector of Fin.Key CompetitorsSCYNEXISNASDAQ:SCYXGain TherapeuticsNASDAQ:GANXImmuneeringNASDAQ:IMRXHomology MedicinesNASDAQ:FIXXReneo PharmaceuticalsNASDAQ:RPHMView All Competitors GEMP Stock Analysis - Frequently Asked Questions How were Gemphire Therapeutics' earnings last quarter? Gemphire Therapeutics Inc (NASDAQ:GEMP) posted its earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15. What other stocks do shareholders of Gemphire Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Micron Technology (MU), Pixelworks (PXLW), SCYNEXIS (SCYX), Alexion Pharmaceuticals (ALXN), Clearside Biomedical (CLSD), Intel (INTC), Iovance Biotherapeutics (IOVA) and Melinta Therapeutics (MLNT). When did Gemphire Therapeutics IPO? Gemphire Therapeutics (GEMP) raised $30 million in an initial public offering (IPO) on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers. This page (NASDAQ:GEMP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
